Cumberland Pharmaceuticals Inc. (CPIX)
| Previous close | 1.6000 |
| Open | 1.4900 |
| Bid | 1.1500 x 200 |
| Ask | 1.8300 x 200 |
| Day's range | 1.4200 - 1.5600 |
| 52-week range | 1.4200 - 2.3600 |
| Volume | |
| Avg. volume | 10,049 |
| Market cap | 20.131M |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4400 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireCUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024.
- PR Newswire
NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced the release of a Special Report evaluating the growing amount of current data supporting the use of its Caldolor® product (intravenous ibuprofen, or IVIB) as a standard of care for the treatment of pain and fever in adults, children and infants.
Insider MonkeyCumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q4 2023 Earnings Call Transcript
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q4 2023 Earnings Call Transcript March 5, 2024 Cumberland Pharmaceuticals Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to Cumberland Pharmaceuticals 2023 Financial Report and Company Update. This call is being […]
